IL326476A - מצמידי נוגדנים אנטי-cd203c והשימוש בהם - Google Patents
מצמידי נוגדנים אנטי-cd203c והשימוש בהםInfo
- Publication number
- IL326476A IL326476A IL326476A IL32647626A IL326476A IL 326476 A IL326476 A IL 326476A IL 326476 A IL326476 A IL 326476A IL 32647626 A IL32647626 A IL 32647626A IL 326476 A IL326476 A IL 326476A
- Authority
- IL
- Israel
- Prior art keywords
- antibody conjugates
- cd203c antibody
- cd203c
- conjugates
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363578246P | 2023-08-23 | 2023-08-23 | |
| US202363595425P | 2023-11-02 | 2023-11-02 | |
| PCT/EP2024/073759 WO2025040820A1 (en) | 2023-08-23 | 2024-08-23 | Anti-cd203c antibody conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL326476A true IL326476A (he) | 2026-04-01 |
Family
ID=92632853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL326476A IL326476A (he) | 2023-08-23 | 2024-08-23 | מצמידי נוגדנים אנטי-cd203c והשימוש בהם |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN121712529A (he) |
| AU (1) | AU2024329275A1 (he) |
| IL (1) | IL326476A (he) |
| MX (1) | MX2026001700A (he) |
| WO (1) | WO2025040820A1 (he) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| PL215901B1 (pl) | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2012113847A1 (en) | 2011-02-25 | 2012-08-30 | Lonza Ltd | Branched linker for protein drug conjugates |
| WO2016115218A1 (en) * | 2015-01-14 | 2016-07-21 | The California Institute For Biomedical Research | Antibody drug conjugates for the treatment of immune conditions |
| WO2019008555A1 (en) | 2017-07-07 | 2019-01-10 | Biocon Limited | POLYMORPHIC FORMS OF DASATINIB |
| AU2021386367A1 (en) * | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN120787162A (zh) * | 2022-05-20 | 2025-10-14 | 诺华股份有限公司 | 抗肿瘤化合物的抗体-药物缀合物及其使用方法 |
| JP2025526418A (ja) * | 2022-07-28 | 2025-08-13 | グラニュラー セラピューティクス リミテッド | 二重特異性抗ｃ－Ｋｉｔ及び抗ＣＤ２０３Ｃ抗原結合分子ならびにそれらの使用 |
-
2024
- 2024-08-23 AU AU2024329275A patent/AU2024329275A1/en active Pending
- 2024-08-23 CN CN202480053109.3A patent/CN121712529A/zh active Pending
- 2024-08-23 WO PCT/EP2024/073759 patent/WO2025040820A1/en active Pending
- 2024-08-23 IL IL326476A patent/IL326476A/he unknown
-
2026
- 2026-02-11 MX MX2026001700A patent/MX2026001700A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121712529A (zh) | 2026-03-20 |
| WO2025040820A1 (en) | 2025-02-27 |
| AU2024329275A1 (en) | 2026-03-19 |
| MX2026001700A (es) | 2026-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304332A (he) | נוגדנים lrrc15 ותצמידים שלהם | |
| GB2610467B (en) | Anti-CLL1 antibody and application thereof | |
| IL284974A (he) | נוגדנים אנטי- cd228ותצמידי נוגדן-תרופה | |
| IL312566A (he) | מולקולות ונוגדנים | |
| GB202017058D0 (en) | Antibodies and uses thereof | |
| IL319931A (he) | נוגדנים אנטי- cd122 ושימושים בהם | |
| EP4069297A4 (en) | ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | |
| IL325624A (he) | תצמידים ושימושים בהם | |
| IL310778A (he) | נוגדנים sirp-אלפא ותצמידים | |
| IL318296A (he) | נוגדן נגד trop2 ומצומד שלו | |
| IL308812A (he) | Neodegrader-anti-cd33 antibody מצמידים | |
| IL320586A (he) | נוגדן נגד trem2 ושימושים שלו | |
| IL310333B1 (he) | ריאגנטים מצמדים ותצמידים שלהם | |
| IL316510A (he) | נוגדן אנטי-b7h3 ושימושיו | |
| EP4437000A4 (en) | ANTI-TREM2 ANTIBODY AND ITS USES | |
| EP4490199A4 (en) | MODIFIED ANTIBODIES AND THEIR USES | |
| IL308485A (he) | צימוד נוגדן הכולל נוגדן אנטי-פ-קדרין ושימושים בו | |
| IL320972A (he) | נוגדנים אנטי-tfr1 ושימושים בהם | |
| IL309048A (he) | תצמידי נוגדן תרופה אנטי- egfrviiiושימושים בהם | |
| IL326476A (he) | מצמידי נוגדנים אנטי-cd203c והשימוש בהם | |
| GB202303531D0 (en) | Antibodies and uses thereof | |
| IL310247A (he) | נוגדנים נקטין-4 ותצמידים | |
| CA3300188A1 (en) | Anti-cd203c antibody conjugates and uses thereof | |
| HK40087054A (en) | Antibody molecule-drug conjugates and uses thereof | |
| HK40113417A (en) | Sirp-alpha antibodies and conjugates |